Mirabilis closes $10.5m in series A extension:
This article was originally published in Clinica
Seattle, Washington-based Mirabilis Medica has received $10.5m in funding after it closed an extension to a series A financing round that initially took place last year. The financing, which adds to the $4m raised during the original round (see Clinica's Medtech Ventures No 1, p 2), was led by Arboretum Ventures. It also included investments from Split Rock Partners, Dow Venture Capital and an individual investor. Mirabilis is seeking funds to back the continued development and testing of its image-guided, high-intensity focused ultrasound (HIFU) system for treating gynaecological diseases.
You may also be interested in...
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.